[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2379067T3 - Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego - Google Patents

Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego

Info

Publication number
PL2379067T3
PL2379067T3 PL09797234T PL09797234T PL2379067T3 PL 2379067 T3 PL2379067 T3 PL 2379067T3 PL 09797234 T PL09797234 T PL 09797234T PL 09797234 T PL09797234 T PL 09797234T PL 2379067 T3 PL2379067 T3 PL 2379067T3
Authority
PL
Poland
Prior art keywords
fingolimod
treatment
multiple sclerosis
dosage regimen
regimen
Prior art date
Application number
PL09797234T
Other languages
English (en)
Inventor
Robert Schmouder
Thomas Dumortier
Olivier David
Michael Looby
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2379067(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2379067T3 publication Critical patent/PL2379067T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09797234T 2008-12-22 2009-12-21 Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego PL2379067T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29
EP09797234.3A EP2379067B1 (en) 2008-12-22 2009-12-21 Dosage regimen for fingolimod for the treatment of multiple sclerosis
PCT/US2009/068888 WO2010075239A1 (en) 2008-12-22 2009-12-21 Dosage regimen for a s1p receptor agonist

Publications (1)

Publication Number Publication Date
PL2379067T3 true PL2379067T3 (pl) 2016-02-29

Family

ID=41667217

Family Applications (3)

Application Number Title Priority Date Filing Date
PL09797234T PL2379067T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego
PL18201062T PL3453387T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania dla agonisty receptora s1p
PL18179301T PL3409274T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania dla agonisty receptora s1p

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL18201062T PL3453387T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania dla agonisty receptora s1p
PL18179301T PL3409274T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania dla agonisty receptora s1p

Country Status (41)

Country Link
US (11) US20100160259A1 (pl)
EP (7) EP3120844A1 (pl)
JP (7) JP2012513401A (pl)
KR (1) KR101347919B1 (pl)
CN (1) CN102264359A (pl)
AR (1) AR074826A1 (pl)
AU (1) AU2009330176C9 (pl)
BR (1) BRPI0923500A2 (pl)
CA (1) CA2747802C (pl)
CL (2) CL2011001529A1 (pl)
CO (1) CO6390117A2 (pl)
CR (1) CR20110274A (pl)
CU (1) CU20110136A7 (pl)
CY (4) CY1116990T1 (pl)
DK (3) DK3453387T3 (pl)
EA (1) EA201100978A1 (pl)
EC (1) ECSP11011222A (pl)
ES (3) ES2760607T3 (pl)
FR (1) FR20C1060I1 (pl)
HN (1) HN2011001759A (pl)
HR (3) HRP20151190T1 (pl)
HU (4) HUE048717T4 (pl)
IL (3) IL213170A0 (pl)
LT (3) LT3409274T (pl)
LU (1) LUC00183I2 (pl)
MA (1) MA32981B1 (pl)
ME (2) ME03802B (pl)
MX (2) MX2011006623A (pl)
NO (1) NO2020038I1 (pl)
NZ (1) NZ593065A (pl)
PE (1) PE20120337A1 (pl)
PL (3) PL2379067T3 (pl)
PT (3) PT3453387T (pl)
RS (2) RS59857B1 (pl)
SG (1) SG171404A1 (pl)
SI (3) SI3409274T1 (pl)
TN (1) TN2011000272A1 (pl)
TW (1) TW201028143A (pl)
UY (1) UY32352A (pl)
WO (1) WO2010075239A1 (pl)
ZA (2) ZA201103863B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785484B2 (en) 2008-03-17 2014-07-22 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
MX2011006623A (es) 2008-12-22 2011-07-12 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p.
CN102548579A (zh) 2009-09-29 2012-07-04 诺瓦提斯公司 S1p受体调节剂的给药方案
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
EA201201515A1 (ru) * 2010-05-06 2013-08-30 Новартис Аг Схема приема производных диарилсульфидов
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
EA026144B9 (ru) 2011-01-07 2021-10-26 Новартис Аг Твердофазная фармацевтическая композиция, содержащая гемифумаратную соль 1-{4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил}азетидин-3-карбоновой кислоты, и таблетка, ее содержащая
WO2012112933A1 (en) 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
CN104540800B (zh) 2012-08-17 2017-05-10 埃科特莱茵药品有限公司 制备(2z,5z)‑5‑(3‑氯‑4‑((r)‑2,3‑二羟基丙氧基)苯亚甲基)‑2‑(丙亚氨基)‑3‑(邻甲苯基)噻唑烷‑4‑酮的方法及在该方法中所用的中间产物
AU2014225534A1 (en) * 2013-03-06 2015-09-24 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
KR20160141841A (ko) * 2014-04-10 2016-12-09 노파르티스 아게 Ｓ１ｐ 조절제 즉시 방출 투여 요법
EP4056179A1 (en) 2014-12-11 2022-09-14 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
NZ771435A (en) * 2015-01-06 2024-08-30 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
JP2023501217A (ja) 2019-10-31 2023-01-18 イドーシア ファーマシューティカルズ リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
ATE412408T1 (de) 2002-05-16 2008-11-15 Novartis Pharma Gmbh Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP2359821A1 (en) * 2004-11-29 2011-08-24 Novartis AG Dosage regimen of an s1p receptor agonist
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP1850689A4 (en) * 2005-02-10 2013-05-22 G I View Ltd TECHNIQUES FOR DISPLACING A GASTROINTESTINAL TOOL EQUIPPED WITH A GUIDING ELEMENT
DK2952177T3 (da) * 2007-10-12 2021-04-26 Novartis Ag Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
US8785484B2 (en) * 2008-03-17 2014-07-22 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
WO2009155475A1 (en) * 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
BRPI0923213A2 (pt) * 2008-12-22 2016-01-26 Novaris Ag regime de dosagem de um agonista do receptor para s1p.
MX2011006623A (es) 2008-12-22 2011-07-12 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p.

Also Published As

Publication number Publication date
LT3409274T (lt) 2020-02-10
US20220142949A1 (en) 2022-05-12
DK2379067T3 (en) 2015-12-07
US20200330407A1 (en) 2020-10-22
US20140148415A1 (en) 2014-05-29
ME03594B (me) 2020-07-20
DK3409274T3 (da) 2019-12-16
US20190091180A1 (en) 2019-03-28
CA2747802C (en) 2021-02-09
JP7329965B2 (ja) 2023-08-21
BRPI0923500A2 (pt) 2018-05-29
IL278914A (en) 2021-01-31
MA32981B1 (fr) 2012-01-02
ES2552823T3 (es) 2015-12-02
RS59857B1 (sr) 2020-02-28
ECSP11011222A (es) 2011-08-31
US20140066657A1 (en) 2014-03-06
CY2020036I2 (el) 2021-06-25
CR20110274A (es) 2011-07-19
CO6390117A2 (es) 2012-02-29
SI3409274T1 (sl) 2020-03-31
HUE048717T2 (hu) 2020-08-28
CN102264359A (zh) 2011-11-30
EP3409274A1 (en) 2018-12-05
EA201100978A1 (ru) 2012-01-30
PE20120337A1 (es) 2012-04-24
EP4098256A1 (en) 2022-12-07
ZA201205942B (en) 2013-03-27
JP2017141238A (ja) 2017-08-17
SI2379067T1 (sl) 2016-01-29
WO2010075239A1 (en) 2010-07-01
PT3409274T (pt) 2019-12-17
FR20C1060I1 (fr) 2020-12-25
JP2019167360A (ja) 2019-10-03
MX2011006623A (es) 2011-07-12
PT2379067E (pt) 2015-12-23
ES2810823T3 (es) 2021-03-09
JP2012513401A (ja) 2012-06-14
HRP20201167T1 (hr) 2020-12-11
JP2024129030A (ja) 2024-09-26
HRP20151190T1 (hr) 2016-01-01
EP3677260A1 (en) 2020-07-08
NO2020038I1 (no) 2020-11-18
EP3120844A1 (en) 2017-01-25
AU2009330176C9 (en) 2017-01-05
KR101347919B1 (ko) 2014-01-07
AU2009330176C1 (en) 2016-12-08
US20160081949A1 (en) 2016-03-24
JP2014144970A (ja) 2014-08-14
PL3409274T3 (pl) 2020-06-01
RS60666B1 (sr) 2020-09-30
SG171404A1 (en) 2011-07-28
IL274756A (en) 2020-07-30
HUE048717T4 (hu) 2022-02-28
US20170189353A1 (en) 2017-07-06
LT3453387T (lt) 2020-08-25
PL3453387T3 (pl) 2020-11-02
AU2009330176A1 (en) 2011-07-07
US20160263061A1 (en) 2016-09-15
UY32352A (es) 2010-07-30
ZA201103863B (en) 2012-10-31
EP3409274B1 (en) 2019-11-20
CL2013001558A1 (es) 2013-10-25
LUC00183I2 (pl) 2024-07-01
EP2379067A1 (en) 2011-10-26
ME03802B (me) 2021-04-20
KR20110096175A (ko) 2011-08-29
EP2379067B1 (en) 2015-09-02
JP2022103194A (ja) 2022-07-07
SI3453387T1 (sl) 2020-10-30
JP2016135752A (ja) 2016-07-28
MX2021010759A (es) 2022-07-19
US20100160259A1 (en) 2010-06-24
NZ593065A (en) 2012-11-30
AU2009330176B2 (en) 2014-03-06
PT3453387T (pt) 2020-08-11
HUE026869T2 (en) 2016-08-29
DK3453387T3 (da) 2020-08-10
TW201028143A (en) 2010-08-01
EP2907511A1 (en) 2015-08-19
CA2747802A1 (en) 2010-07-01
CY1122812T1 (el) 2021-05-05
US20110257133A1 (en) 2011-10-20
IL213170A0 (en) 2011-07-31
CY2020036I1 (el) 2021-03-12
LTPA2020005I1 (lt) 2020-12-10
HUE052048T2 (hu) 2021-04-28
CY1123255T1 (el) 2021-10-29
US20180289638A1 (en) 2018-10-11
CL2011001529A1 (es) 2012-02-24
HRP20192175T1 (hr) 2020-03-20
TN2011000272A1 (en) 2012-12-17
AR074826A1 (es) 2011-02-16
CU20110136A7 (es) 2012-01-31
EP3453387B1 (en) 2020-06-03
CY1116990T1 (el) 2017-04-05
HN2011001759A (es) 2013-11-26
ES2760607T3 (es) 2020-05-14
HUS2000046I1 (hu) 2020-12-28
EP3453387A1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
PT2379067E (pt) Regime de dosagem para fingolimod para o tratamento de esclerose múltipla
HK1255133A1 (zh) 治療多發性硬化症的富馬酸二甲酯的劑量方案
TWI561257B (en) Extended release oral acetaminophen/tramadol dosage form
IL232222B (en) Antibody to cd20 for use as a drug to treat multiple sclerosis
IL207128A0 (en) Pharmaceutical dosage form
HK1180233A1 (zh) 用於吸附劑在腸內的經口遞送的製劑
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
HK1167809A1 (en) Oxidation-stabilized tamper-resistant dosage form
EP2410855A4 (en) PROCESS FOR THE PREPARATION OF ALOGLIPTIN
IL264349B1 (en) Regimens containing neratinib for the treatment of cancer
ZA201402907B (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
EP2632889A4 (en) INTERMEDIATE COMPOUNDS AND METHOD FOR THE PRODUCTION OF FINGOLIMODE
ZA201008222B (en) Process for the synthesis of arformoterol
ZA200903858B (en) Pharmaceutical dosage form
IL209360A (en) Medications containing pm00104 for the treatment of multiple myeloma
IL248919A0 (en) Pediatric compounds for the treatment of multiple sclerosis
GB0803054D0 (en) Medicament
HK1139050A1 (en) Medicament for the treatment of pneumonia
EP2373306A4 (en) ALISKIRENE WITH TRANSVERSE ADMINISTRATION
PL2229943T3 (pl) Związek do zastosowania w leczeniu neuropatii obwodowych
EP2641609A4 (en) THERAPEUTIC AGENT FOR MUSCLE DYSTROPHY
GB0918912D0 (en) Improved medicament formulation
GB0802576D0 (en) Dosage form
IL226042A (en) Intermediates and methods for making pingolimod
PL394512A1 (pl) Srodek stomatologiczny przeznaczony do leczenia endodontycznego oraz sposób jago wytwarzania